Bellicum enters license agreement with unc lineberger and mass general for use of caspacide® safety switch

Houston, june 28, 2021 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the university of north carolina lineberger comprehensive cancer center (unc lineberger) and massachusetts general hospital (mass general) covering certain intellectual property and technology rights regarding the company's caspacide (inducible caspase-9, or ic9) safety switch and related technologies, and the use of rimiducid. caspacide may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in the pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next generation higher potency cell therapy constructs.
BLCM Ratings Summary
BLCM Quant Ranking